Cytogen, Inc. (KOSDAQ:217330) shares have retraced a considerable 29% in the last month, reversing a fair amount of their solid recent performance. Still, a bad month hasn’t completely ruined the past year with the stock gaining 46%, which is great even in a bull market.
After such a large drop in price, Cytogen may look like a strong buying opportunity at present with its price-to-sales (or “P/S”) ratio of 5.9x, considering almost half of all companies in the Biotechs industry in Korea have P/S ratios greater than 16.3x and even P/S higher than 102x aren’t out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it’s justified.
